Open AccessEndothelial dysfunction and hemostasis in acute myocardial infarction before and after Trombovazim therapy
Author(s) -
Ye. F. Kotovshchikova,
Ye. I. Buevich,
Ye. N. Syulzhina,
Indira Tarasova,
Ye. I. Vereschagin,
Л. А. Попова
Publication year - 2011
Publication title -
bûlletenʹ sibirskoj mediciny
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.135
H-Index - 3
eISSN - 1819-3684
pISSN - 1682-0363
DOI - 10.20538/1682-0363-2011-1-150-156
Subject(s) - hemostasis , osteoprotegerin , medicine , von willebrand factor , myocardial infarction , platelet , coagulation , vascular endothelial growth factor , cardiology , endothelial dysfunction , gastroenterology , endocrinology , vegf receptors , receptor , activator (genetics)
We studied 57 patients with acute myocardial infarction (AMI) aged 20 to 63 years. Initially (day 25 from disease onset), Fibroblast growth factor (FGF), osteoprotegerin, vascular endothelial growth factor (VEGF-A), von Willebrand factor (vWF) were determined in patients’ blood by immunoenzyme method; hemostasis system was examined. The control group consisted of 15 healthy volunteers aged 19 to 50 years. The patients were divided into two groups: the major group was receiving Trombovazim in dosage 800 mg per day during 1 month together with the standard therapy of AMI, and the control group, which was receiving no Trombovazim. Control study of the dynamics of FGF, osteoprotegerin, VEGF-A, vWF, and hemostasis hemostasis parameters was performed after 1 month of treatment with Trombovazim. The inclusion of Trombovazim into the complex therapy of AMI was found to result in a decrease in FGF, osteoprotegerin, and VEGF-A levels due to the endothelial protection effect and apoptosis control. The parameters of vascular-platelet and coagulation hemostasis components had no significant changes.